Monday, December 15, 2008

Cocaine and other Drug Products of the Past











Cocaine toothache drops (c. 1885) were popular for children.
Not only would the medicine numb the pain, but it could also put the user in a “better” mood.
Bayer heroin bottle. From 1898 to 1910 heroin was marketed as a non-addictive morphine substitute and cough medicine for children!
Metcalf’s Coca Wine was one of a large number of cocaine-containing wines available on the market.
All claimed medicinal effects, although they were undoubtedly consumed for their “recreational” value as well.
Vin Mariani (c. 1865) was the leading Coca Wine of its time.
Pope Leo XIII purportedly carried a hipflask of Vin Mariani with him, and awarded a Vatican gold medal to its creator, Angelo Mariani.
Coca wine was made by the Maltine Manufacturing Company (New York). The dosage indicated on the back of the bottle reads: “A wine glass full with, or immediately after, meals. Children in proportion.”
Cocaine-containing throat lozenges (c. 1900) were “indispensable for singers, teachers, and orators.” In addition to quieting a sore throat, these lozenges undoubtedly provided the “pick-me-up” to keep these professionals performing at their peak.
Paperweight advertisement for C.F. Boehringer & Soehne (Mannheim, Germany), “largest makers in the world of quinine and cocaine.” This chemical manufacturer was proud of its leading position in the world’s cocaine market.
This bottle of Stickney and Poor’s paregoric (mixture of opium and alcohol) was distributed much like the spices for which the company is better known. Doses for infants, children, and adults are given on the bottle. At 46% alcohol, this product is 92 proof which is pretty potent in itself.
This ad is for Glyco-Heroin manufactured by Martin H. Smith Company (New York). Heroin was widely used not only as an analgesic but also as a remedy for asthma, coughs, and pneumonia. Mixing heroin with glycerin (and often adding sugar or spices) made the bitter-tasting opiate more palatable for oral consumption.
This National Vaporizer Vapor-OL (opium) Treatment no. 6 for asthma may have provided a unique method of essentially “smoking” opium. The volatile liquid was placed in a pan that was heated by a small kerosene lamp (see below). Other substances were also used in these early (c. 1890) vaporizers, but this mixture probably ensured plenty of visitors for the spasmodically affected.

Wednesday, November 19, 2008

US teen lives 118 days without heart

By Jim Loney

MIAMI, Nov 19 (Reuters) - An American teen-ager survived for nearly four months without a heart, kept alive by a custom-built artificial blood-pumping device, until she was able to have a heart transplant, doctors in Miami said on Wednesday.

The doctors said they knew of another case in which an adult had been kept alive in Germany for nine months without a heart but said they believed this was the first time a child had survived in this manner for so long.

The patient, D'Zhana Simmons of South Carolina, said the experience of living for so long with a machine pumping her blood was "scary."

"You never knew when it would malfunction," she said, her voice barely above a whisper, at a news conference at the University of Miami/Jackson Memorial Medical Center.

"It was like I was a fake person, like I didn't really exist. I was just here," she said of living without a heart.

Simmons, 14, suffered from dilated cardiomyopathy, a condition in which the patient's heart becomes weakened and enlarged and does not pump blood efficiently.

She had a heart transplant on July 2 at Miami's Holtz Children's Hospital but the new heart failed to function properly and was quickly removed.

Two heart pumps made by Thoratec Corp (THOR.O: Quote, Profile, Research, Stock Buzz) of Pleasanton, California, were implanted to keep her blood flowing while she fought a host of ailments and recovered her strength. Doctors implanted another heart on Oct. 29.

"She essentially lived for 118 days without a heart, with her circulation supported only by the two blood pumps," said Dr. Marco Ricci, the hospital's director of pediatric cardiac surgery. During that time, Simmons was mobile but remained hospitalized.

When an artificial heart is used to sustain a patient, the patient's own heart is usually left in the body, doctors said.

In some cases, adult patients have been kept alive that way for more than a year, they said.

"This, we believe, is the first pediatric patient who has received such a device in this configuration without the heart, and possibly one of the youngest that has ... been bridged to transplantation without her native heart," Ricci said.

Simmons also suffered renal failure and had a kidney transplant the day after the second heart transplant.

Ricci said her prognosis was good. But doctors said there is a 50 percent chance that a heart transplant patient will need a new heart 12 or 13 years after the first surgery. (Editing by Cynthia Osterman)

Claudia Castillo gets windpipe tailor-made from her own stem cells

A woman has been given a new section of windpipe created from her own stem cells in an operation that could revolutionise surgery.

Claudia Castillo, 30, who lives in Barcelona, has become the first person to be given a whole organ tailor-made for her in laboratories across Europe.

A graft from a donor was used, but because it has been imbued with Ms Castillo’s own cells, there is no sign that her body will reject the organ. Researchers and surgeons from Britain, Italy and Spain collaborated to grow tissue from Ms Castillo’s own bone marrow stem cells, using them to fashion the new bronchus – a branch of the windpipe. They believe that one day the approach will be used to create engineered replacements for other damaged organs, such as the bowel or bladder. In five years they hope to begin clinical trials in which laboratory-made voice boxes are implanted into patients with cancer of the larynx.

Martin Birchall, of the University of Bristol, a British member of the team, said: “This is the first time a tissue-engineered whole organ has been transplanted into a patient. I reckon in 20 years’ time it will be the commonest operation – it will transform the way we think about surgery.”

Ms Castillo, who was born in Colombia, had suffered a tuberculosis infection that ravaged her airways, leaving her unable to do simple domestic tasks. Disease had caused her windpipe, or trachea, to collapse just at the point where it entered her lung. Without the pioneering operation in June, the lung would have been removed. Today she again has a normal life and is able to look after her two children. She can walk up stairs without getting breathless and has even been dancing.

The prospect of the patient needing powerful drugs to avoid rejection had been thought to outweigh any potential benefits of trachea transplants. Four months on, Ms Castillo’s doctors have seen no sign of her immune system rejecting the transplant, even though she has had no immunosuppres-sive drugs.

Details of the transplant, performed by Paolo Macchiarini, at the Hospital Clinic of Barcelona, are published online today by The Lancet.

First a section of trachea was taken from a donor and stripped of cells that could cause an immune reaction, leaving a grey trunk of connective tissue. Stem cells were then taken from Ms Castillo’s bone marrow and grown in Professor Birchall’s laboratory. Stem cells can develop into different kinds of tissue, given the right chemical instructions, enabling researchers to cultivate cartilage and epithelial cells to cover the 7cm graft. It was then “seeded” with the new cells using a process developed in Milan. Finally the trachea, covered in cartilage and lined with epithelial cells, was cut to shape and fitted.

Professor Macchiarini said: “The probability that this lady will have rejection is almost zero. She is enjoying a normal life, which for us clinicians is the most beautiful gift.”

The researchers said that the surgery could help some patients in Britain but admitted that the procedure was too expensive to be widely available. They are seeking EU funding and commercial sponsors for trials to create and transplant a larynx, an operation that could be more cost-effective.

Ms Castillo said: “I was scared at the beginning because I was the first patient – but trusted the doctors. I am now enjoying life and am very happy that my illness has been cured.”

Friday, October 3, 2008

In Some Cultures, Cancer Stirs Shame

In Some Cultures, Cancer Stirs Shame
By LUCETTE LAGNADO

When Mildred Wong received a diagnosis of breast cancer last year, she faced two tough decisions: what treatment to pursue and whom, if anyone, to tell about it.
Secret Treatment

Brooklyn's Maimonides Cancer Center takes pains to break through barriers to care among ethnic and minority groups.

In Mrs. Wong's native China, people often keep illnesses like cancer a secret. That tradition continues even here in America, where her family settled in the 1950s. Years ago, Mrs. Wong's infant daughter developed a brain tumor and her own mother insisted she tell no one. When the baby died, the grandmother tried to dissuade Mrs. Wong from attending the funeral, so great was the stigma.

Now, as she stares down her own health crisis, memories of her family's long-buried wounds are rushing in. "I came from a cultural background of stoic acceptance, saving face, keeping quiet," she explains.

Mrs. Wong, 60 years old, sought treatment at Maimonides Cancer Center, located on the edge of Brooklyn's booming Chinatown. Its patients are an ethnic tapestry of Chinese-Americans, Hasidic Jews from nearby Borough Park, Russians from Coney Island, Pakistani Muslims, as well as some Caribbean and African-Americans. Though starkly diverse, these groups often share strong beliefs about keeping a cancer diagnosis -- and possible treatments -- under wraps. The subject is such a cultural taboo that families have been known to shield loved ones from the seriousness of their condition. Some patients are reluctant to seek or heed medical advice; others even refuse to utter the word "cancer."

With ethnic minorities and immigrants fast becoming the collective U.S. majority, there is a push in medical circles to be more sensitive to cultural nuances. In 2001, the National Cancer Institute established the Center to Reduce Cancer Health Disparities to study why mortality rates for cancer can be so much higher for some groups than others. Only 71% of African-American women, for instance, survive for five years after a cancer diagnosis, compared to 86% of white women. Issues such as poverty, lack of access to care and inadequate care, are among probable reasons for the gap. But cultural factors, says the NCI center's director, Dr. Tanya Springfield, are now being recognized as a "significant" part of the problem.

Maimonides is among several hospitals nationwide attempting to hit these issues head on. In addition to dispensing medical advice to individuals, doctors routinely confer with family members, rabbis and other religious leaders as part of some patients' care. The facility has several Asian oncologists on staff who speak Chinese dialects fluently. As a nod to discretion, the center is located about a mile from the main hospital and lacks any overt signage referring to its true mission of cancer treatment. A back entrance and a special waiting room with frosted glass help visitors go undetected.
Balancing Act

Staff at the four-year-old facility balance a complicated set of cultural mores and medical responsibilities. The range of attitudes "makes our job very difficult," says Dr. Yiqing Xu, a Chinese-born oncologist.

U.S. law dictates that patients be informed about their conditions and consent to all medical treatments. Those who submit to chemotherapy or other therapies are required to sign forms that spell out the drugs they are receiving, as well as possible side effects. However, consent forms tend to be in English, as Dr. Xu points out. And many families -- especially Chinese, Russians and Muslims -- often want their loved ones to know as little as possible about their cancer.

Sze Cheng's 72-year-old grandmother, born in China, was recently found to have advanced colon cancer. But Ms. Cheng and her husband have been determined to play down the true nature of her situation -- despite advice from a Maimonides doctor.

"We try to do what is best for her," explains Ms. Cheng, who says she loves her grandmother very much. "We talked about telling her," adds her husband, Sheng Lam. "But if we tell her, she will be upset -- she will go into a depression."

Oncologist Yiwu Huang says he worked with the family to explain the consent form to his patient. He says he told the woman, who does not speak English, that she had a growth in her colon, and that the chemotherapy was a "medication to try to prevent the disease from coming back." Still, "I avoided the word 'cancer,'" he says. He beseeched the family to be more direct, he says, but to no avail. "They said, 'please don't tell her,'" the doctor recalls.

"It is not uncommon in Chinese families to hide the news," notes Dr. Xu. But while she and other doctors may defer to families, some bristle at doing so. "It is not good for the patient," says Dr. Xu. "They don't have a chance to have a say in their treatment. It should be what they want, not what their families want." She pauses, then adds: "I may be too Americanized in my views."

Alan Astrow, Maimonides's director of Hematology-Medical Oncology, says that good medical practice calls for full disclosures. "But in many traditional cultures, crucial decisions are made by the patients' family -- we treat people from all over the world. Is there a conflict? Yeah there is a conflict." While it is necessary for doctors to follow the law, he says, it is also important that clinicians be mindful of the feelings and values of both patient and family.

The center's doctors have learned to modulate their vocabulary. For example, "we don't use the term chemotherapy," says Dr. Xu. Instead, she will merely say "treatment." To get around the "C" word, she might use substitutes such as "lesion" or "mass."

Many patients welcome the edited approach. Malka Friedman, a devout Orthodox Jew, prefers to avoid all direct reference to the disease. "The word is like a sword -- this is the way we were brought up," says Mrs. Friedman. Merely to say "cancer," she believes, could somehow give malignant cells more power to spread.

Upon learning that she needed a mastectomy, Mrs. Friedman added an unofficial member to her medical team. During an appointment with her breast surgeon, she placed a call to her rabbi and had him speak to the doctor.

"It was one of my first experiences with a rabbi calling and saying 'We have been praying over this and we have gotten guidance and we don't want major surgery to be done,'" Dr. Patrick Borgen, her surgeon at Maimonides, recalls. (He agreed to perform a less-radical procedure.) Now, he says he has learned to expect that rabbis will weigh in on medical decisions.

A gentle yet strong-willed woman, Mrs. Friedman's faith dictated she cover her head with a wig even before chemotherapy. She refers to Dr. Borgen, chief of breast surgery, as "a messenger of God." Still, the 61-year-old doesn't always do what he asks.

Dr. Borgen encouraged his patient to take a test to determine if she is a carrier of a particular genetic mutation -- one way to predict if a woman might be at a high risk for developing other cancers. He further advised that her female relatives have the same test.

She refused. Instead, Mrs. Friedman says she told her daughters and other kin to go for regular medical check-ups.

Cancer is considered to be something of a social blemish in the tightly-knit Orthodox community. Merely being seen entering or leaving a cancer center might spark rumors that could have profound repercussions for a family. A young person who has suffered from the disease, for instance, is generally considered an undesirable marriage partner. Cancer in a parent or sibling also could affect one's marital prospects.

Across backgrounds, the forces of denial don't discriminate. Over the years, several hospitals have worked to try to persuade African-American women to get early screening for breast cancer -- only to find that some won't come back even when told they have a tumor.

In Atlanta, for example, the Georgia Cancer Center for Excellence reaches out to black women at churches and health fairs. Such targeted efforts have yielded results: Patients coming in with advanced, Stage Four cancers declined from 16.8% to 9% between 2001 and 2005. Even so, anywhere from 7% to 10% of women found to have cancer either fail to return or don't stay through the entire course of treatment, according to Dr. Mitchell Berger, Chief of Hematology and Oncology at the center, a division of Grady Health System.

"There are so many myths that can influence a person's tendency to seek care or refuse care -- there are many examples from Harlem to Appalachia to Native America," says Dr. Harold Freeman, founder of the Harlem-based Ralph Lauren Center for Cancer Care and Prevention. The center is a joint venture of Memorial Sloan-Kettering Cancer Center and North General, a local Harlem hospital.

"We need to be careful. It is very tough to separate race from poverty from culture, yet you need to do that," he says.
Culture Cues

Since arriving in Harlem in the 1960s, where he recalls seeing women with cancers so advanced as to be inoperable, Dr. Freeman has seen the need to address cultural points of difference.

One approach is to be mindful of patients' own myths and taboos -- then figure out ways to get them into treatment. At the Lauren center, for example, patients are assigned a "navigator" -- an employee charged with walking them through the different phases of their diagnosis and care. That can mean phoning people who don't show up for an appointment, or even knocking on their door at home if they go missing at any point during treatment.

Monica Williams, 70 years old, arrived at the Harlem center three years ago. Born in Grenada, Ms. Williams is a devout Catholic who says she had a premonition that she was ill. Years before her diagnosis, she recalls having a nightmare: "A voice said to me, 'You have cancer,' and I said, 'Get away from me, you devil.'" She remembered the dream when she learned she had colon cancer. She believed that God, not doctors, had the power to heal her.

Maud Colas, the patient navigator assigned to Ms. Williams, recalls painstaking sessions to get her to agree to treatment -- even while respecting her religious convictions. The feisty septuagenarian, herself a home health-care aide, at first wouldn't budge. Ms. Colas, who is also of Caribbean descent, appealed to Mrs. Williams to reconsider.

"I had barriers too, and I said, 'I also love God, but give our doctors a try,'" Ms. Colas recalls. She helped work out a solution: Mrs. Williams agreed to let the doctors perform surgery to remove her tumor -- while praying to God to guide them.

Ms. Williams, a proud woman who shows up to the center impeccably dressed -- she sported a pink gauze ensemble one recent afternoon -- has since endured numerous rounds of chemotherapy. All the while, she has continued her work. Yet still she harbors her secret, having told no one, not even immediate family, about her condition. When her hair started falling out as the result of chemo, she waved it off as a bad experience at the hairdresser. Asked if perhaps her husband and other relatives may have guessed the truth, she replies only: "Maybe."

Ms. Williams's cancer was fairly advanced when she was diagnosed. Then a lesion was found in her liver and she needed more surgery. As of now, says Dr. Freeman, there is no evidence of the disease. Ms. Williams says she has made her peace with human medical interventions. "I ask God to lift me up," she says.

As for Mrs. Wong, she came to a major decision this year: She would be more American than Chinese in dealing with her breast cancer. She couldn't forget how desperately alone she had felt when her baby was ill. "I didn't tell anyone, and no one came to visit," she says. In the months when the infant lay in a hospital, friends and relatives heard only that she suffered from a cold.
Difficult News

When she was first diagnosed with breast cancer, she sought a second opinion at Maimonides. The news was hard to bear. Given that the cancer had spread to a lymph node, Dr. Borgen, her surgeon, suggested treatment that would include a single mastectomy as well as chemotherapy.

Instead of keeping her fears about breast cancer bottled inside, she reached out to friends, both Chinese and American. She also leaned on members of her Baptist church where she and her husband are active. She has even attended a few meetings of a Chinese cancer support group. Without the burden of her mother's insistence on secrecy, Mrs. Wong says she was strangely liberated. "I felt totally different this time because of the love and support of my friends," she recalls. "They came over and cooked and shopped."

After surgery came a grueling round of chemotherapy. She still recalls the horror of seeing her hair fall out. She took an American step she had heard was "empowering." She shaved her head.

"You do feel better," afterwards, she says, adding that she went and bought a couple of wigs. She still wears one of them, even though her treatment is finished. "My prognosis is very good, and I am very grateful."

Firms Struggle With Varied Rules on Melamine

Firms Struggle With Varied Rules on Melamine
By SKY CANAVES
*
HONG KONG -- Differing and shifting government regulations have complicated food companies' efforts to grapple with the widening Chinese tainted-milk scandal, leading to outright bans in some places for products that pass official muster in others.

U.S. regulators Friday said food products wouldn't raise health concerns if they contained levels below 2.5 parts per million of melamine, an industrial chemical at the center of the tainted-milk scandal. But they said they won't tolerate the use of melamine as a food additive, saying they couldn't determine a safe level for use in infant formula, citing gaps in scientific knowledge about its effect on babies. The agency said tainted formula hasn't been found in the U.S. (Statement)
[testing limits chart]

Meanwhile, other regulators around the world are scrambling to establish melamine limits where none previously existed. Taiwan had no standard until last week, when it set a tough limit of 0.05 parts per million. That led to a recall this week of Nestlé SA products after regulators said they found traces of melamine in Nestlé products made in China. Nestlé said that its products are safe and that the small traces found by Taiwan "exist in the natural food cycle."

Last week, Indonesian authorities announced that they had found melamine in a dozen Chinese-made products, including Nabisco Oreo wafers and Mars M&M's and Snickers, in quantities ranging from 8.5 to 945 parts per million. Mars Inc. and Kraft Foods Inc., which owns Nabisco, questioned the results, pointing to other jurisdictions where test results for the same Chinese-made products came up clean.

An Indonesia Food and Drug Control Agency spokeswoman, reached late Friday, said, "It is no surprise if the industry has complained, but that does not lessen its result." She said Indonesia follows World Health Organization guidelines for melamine levels, which are based on U.S. standards involving weight and diet. In a report issued last week, however, the WHO said that the U.S. approach "has a large uncertainty" due to the lack of data about the effects of various types of melamine and its interaction with other substances.

Multinational firms have warned that adopting tougher standards than those of the U.S. and Europe could lead to higher food costs and product unavailability. "If governments start adopting low tolerance reporting levels, that will have huge implications for many countries where most foods produced in those countries won't pass the test," said Khaled Rabbani, director of corporate and regulatory affairs for Asia Pacific for Mars.

Daniel Chan, a professor of nephrology at the University of Hong Kong, sees the justification for the tougher standards in Hong Kong and Taiwan. "Ideally, we would want none of it," he said. "But if that would have implications with the availability of choices or prices of materials involved, then we have to decide how far we're willing to be exposed to it."

Hong Kong adopted rules Sept. 23 that set a limit of one part per million for children under the age of three and women who are pregnant or breastfeeding. For others, the territory adopted the European Union's standard of 2.5 parts per million. By comparison, one brand of milk powder implicated in the scandal, made by China's Shijiazhuang Sanlu Group Co., had levels exceeding 2,500 parts per million in powdered form, according to Chinese authorities.

In Asia, parts of which import far more food from China than in the West, there's a heightened sense of vulnerability to tainted products. Thousands of products have been tested so far in a number of countries.

Melamine's presence in Chinese-made baby formula has been blamed for the deaths of as many as four infants and sickening more than 50,000 others. China is still working on national standards, and Friday it posted a notice on the Web site of the Ministry of Science and Technology inviting the public to submit methods for detecting melamine in quantities of less than two parts per million within 30 minutes.

The chemical is generally considered safe for adults in minute amounts by other agencies that follow U.S. and EU standards. But little is known about the long-term health effects of the chemical that first rose to prominence as a contaminant a year ago during a tainted pet food scandal in the U.S.

In the U.S., the FDA has limited recall power, and it relies on manufacturers to pull questionable products off shelves. Since it warned against selling or eating one brand of Chinese-made candy called White Rabbit Creamy Candy, state officials in California, Connecticut and others have found it on shelves and warned consumers.

After promising to take a "zero tolerance" approach to melamine, on Sept. 24 Taiwan's health authorities said they would adopt the EU standard.

Sunday, September 7, 2008

Hearing Aids Go Hi-Tech


PURE from Siemens is the latest in hearing aid technology that not only boasts a discreet design, but it is also unparalleled in sound amplification and signal-processing technology. This new device enables wearers to access Bluetooth-enabled devices wirelessly, including phones and MP3 players.

Wednesday, September 3, 2008

Patients 'free from cancer' after immune-boost treatment

Cancer patients have been left free of the disease after being treated with a new drug which harnesses the power of their own immune cells.
# Cancer and immunotherapy Q and A
# Immunotherapy: could it be the cure for cancer?
# Cancer patient recovers after injection of immune cells

Four of 38 patients with non-Hodgkin's lymphoma have seen "complete regressions" following treatment, while five others saw reductions of 50 per cent in their tumours.

Immunotherapy for cancer
While the trials were only carried out on patients with blood cancer, it is hoped the methods can be adapted to tackle other cancers

The drug, which could prove cheaper than other therapies that try to achieve the same effect with cells, works by activating the body's own defences to attack the cancer.

The results have been described as an "exciting" and "significant" development in the use of immunotherapy, the process of using the body's own immune system to fight disease.

While the trials were only carried out on patients with the blood cancer, it is hoped the methods can be adapated to tackle other cancers.

The disease claims the lives of more than 150,000 people in the UK every year and more than one million people are suffering from cancer at any one time.
advertisement

Earlier this year doctors announced that a patient with advanced skin cancer was free of the disease two years after they injected him with billions of his own immune cells using a different method. However, experts warned at the time that the process could prove extremely expensive.

The development of the drug could prove a much cheaper alternative way of providing immunotherapy treatments.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "These exciting preliminary results come from using them to harness the body's own immune response in a new way. Although the side effects need to be monitored carefully, we hope that this type of treatment will prove to be active in larger trials in the future"

"This a significant study," said Dr Cassian Yee, Fred Hutchinson Cancer Research Center, Seattle, who has had significant results using the alternative method of treating patients with white blood cells grown in the lab.

"It remains to be seen if most of the responses are longlasting. Certainly the results are very promising."

The drug, which has been developed by Micromet, in Bethesda, Maryland, was trialled by a team led by Dr Ralf Bargou at University of Würzburg in Würzburg, German.

The results, published in the journal Science, are encouraging because they suggest that the bigger the dose, the bigger the effect.

Coauthor of the study Dr Patrick Baeuerle, of Micromet, said all seven who received the highest dose responded to the drug.

"Two of the seven had a complete response, and five a partial regression (greater than 50 per cent reduction of tumour).".

The longest duration of a response was so far seen in a patient who received one quarter of their dose. After 13 months, he remains free of the blood cancer.

There are adverse side effects involved, however, such as fevers and chills, occasionally with confusion and tremor, though all stopped after treatment ceased.

Now a further trial is investigating how the drugs works in patients with another form of blood cancer, called acute lymphoblastic leukaemia.

Trials with a similar drug are also under way on patients with another type of cancer, which affects glandular tissue and can appear in the lungs, prostate, breast, colon and elsewhere in the body.

Micromet targets the body's own white blood cells on the cancer, using a fraction of a millionth of a gram of a specialised protein called a "bispecific antibody".

The company has created antibodies, called BiTE antibodies, which are able to stick to sites with exquisite precision, in this case to activate specialised white blood cells ( T cells) to attack cancer.

The antibodies overcome a key problem with immunotherapy that as tumours become more advanced they become more "invisible" to the T cells because the cancer cells lack molecules for white blood cells to hang on to and stage their attack.

Normal antibodies are designed to latch on to one molecular target but the bispecific antibody developed by Micromet, given the name blinatumomab, binds to two, the cancer cell and the T cell, and bring the two together to target the immune system on the cancer.

The team tried varying doses of blinatumomab in patients, and found that among 38 patients, at doses from 0.0005 to 0.06 milligrams (millionths of a gram) per square metre of body surface per day, 11 of them exhibited major responses and tumour shrinking. The disease was cleared from bone marrow, spleen and liver too.